Reviewed Mar 2026 | PubMed sources
Active Market
United Kingdom is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Ipamorelin vs Tesamorelin: Head-to-Head Comparison

Ipamorelin (ghrelin pathway) and tesamorelin (GHRH pathway) stimulate GH through different mechanisms. Tesamorelin is FDA-approved for HIV lipodystrophy with proven visceral fat reduction, while ipamorelin offers the cleanest side-effect profile of any GHRP but lacks FDA approval.

Approved Comparison Routing

Approved options in this comparison

A
Tesamorelin

Tesamorelin is currently modeled on this site as an approved treatment path for: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Brand names in the current dataset: Egrifta, Egrifta SV.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Tesamorelin with a provider?

Tesamorelin is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Side-by-Side Comparison

DimensionIpamorelinTesamorelin
Evidence LevelPhase II trialsPhase III trials, FDA-approved
FDA StatusNot approvedFDA-approved (Egrifta)
MechanismGhrelin receptor agonistGHRH analog
Primary UseGH optimization, body composition, anti-agingVisceral fat reduction (HIV lipodystrophy)
Side EffectsMinimal; no cortisol/prolactin impactArthralgia, injection site reactions, edema
CostModerate (research peptide)Very high (branded pharmaceutical)
Fat Reduction EvidenceIndirect via GH elevationDirect clinical evidence for visceral fat reduction
Evidence Level
Ipamorelin
Phase II trials
Tesamorelin
Phase III trials, FDA-approved
FDA Status
Ipamorelin
Not approved
Tesamorelin
FDA-approved (Egrifta)
Mechanism
Ipamorelin
Ghrelin receptor agonist
Tesamorelin
GHRH analog
Primary Use
Ipamorelin
GH optimization, body composition, anti-aging
Tesamorelin
Visceral fat reduction (HIV lipodystrophy)
Side Effects
Ipamorelin
Minimal; no cortisol/prolactin impact
Tesamorelin
Arthralgia, injection site reactions, edema
Cost
Ipamorelin
Moderate (research peptide)
Tesamorelin
Very high (branded pharmaceutical)
Fat Reduction Evidence
Ipamorelin
Indirect via GH elevation
Tesamorelin
Direct clinical evidence for visceral fat reduction

Peptide Overviews

Ipamorelin

BHuman Studies

Ipamorelin is a selective growth hormone secretagogue that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin levels.

Growth Hormone SecretagoguesNot Approved
View full Ipamorelin profile →

Tesamorelin

AFDA Approved

Tesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Growth Hormone SecretagoguesFDA Approved
View full Tesamorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Ipamorelin vs Tesamorelin: FAQ